Merck & Co., Inc. (NYSE:MRK – Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $8.53-8.65 for the period, compared to the consensus EPS estimate of $8.56. The company issued revenue guidance of $63.1-64.3 billion, compared to the consensus revenue estimate of $63.81 billion. Merck & Co., Inc. also updated its FY 2024 guidance to 8.530-8.650 EPS.
Merck & Co., Inc. Stock Performance
MRK traded up $0.47 during trading on Friday, reaching $131.19. 7,757,292 shares of the company’s stock were exchanged, compared to its average volume of 8,336,532. The company has a market capitalization of $332.31 billion, a P/E ratio of 937.07, a PEG ratio of 1.65 and a beta of 0.38. The company has a quick ratio of 1.00, a current ratio of 1.25 and a debt-to-equity ratio of 0.89. The business has a 50 day moving average price of $126.41 and a 200 day moving average price of $115.88. Merck & Co., Inc. has a fifty-two week low of $99.14 and a fifty-two week high of $133.10.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings data on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. The company had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.21 billion. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $1.40 EPS. As a group, analysts predict that Merck & Co., Inc. will post 8.57 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on MRK
Insider Activity
In related news, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $124.89, for a total transaction of $124,890.00. Following the completion of the sale, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares of the company’s stock, valued at $2,991,346.35. The disclosure for this sale can be found here. Insiders own 0.09% of the company’s stock.
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Stocks Leading the U.S. Agriculture Comeback
- Learn Technical Analysis Skills to Master the Stock Market
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Is WallStreetBets and What Stocks Are They Targeting?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.